Career Development Program in Substance Use and Addiction Medicine

项目摘要 培训下一代临床医生-研究人员进行转型，独立，患者- 面向成瘾的研究，将改善那些与成瘾性疾病的生活是最高的公众 健康的重要性，是这个MGH K12指导临床科学家发展奖的主要目标， 药物滥用和成瘾更新申请。这一更新将支持和加强多学科2-3 为期一年的强化培训计划，指导研究，并致力于职业发展导师， 多元化，才华横溢，博士后临床医生，科学家致力于独立的研究事业，在病人， 在成瘾研究实验室丰富的培训环境中提供面向成瘾研究的培训， 在马萨诸塞州总医院（MGH），在MGH，姆克林先进的教学培训机会 医院和哈佛医学院（HMS）。这些资源将继续根据每个国家的具体情况加以调整。 学者的兴趣，以提供重点，集中的培训和指导经验， 最佳地推进每个学者的生产，独立，有影响力的成瘾为重点的工作，准备他们 在临床和学术医学，政府和行业的领导角色。职业发展支助 在更新将得到支持的合作与一个新的国家联盟的NIDA K12学者和 导师Eden Evins，医学博士，公共卫生硕士和Nancy Rigotti，医学博士将再次合作，作为联合PI领导职业生涯 发展计划更新，监督学者的研究和职业发展，学术生产力， 并在以病人为导向的成瘾研究中取得独立。他们致力于吸引 由一个扩大的执行委员会和一个3- 成员咨询委员会的经验丰富的领导人成功的研究生医学培训计划， 确定、招聘、留住和促进医学界代表性不足的人的职业发展 候选人mPI是精神病学系（Evins博士）和医学系（Evins博士）的HMS教授。 Rigotti）。他们和他们的部门有着长期的富有成效的合作历史，并有着共同的愿景， 扩大多元化，独立的临床成瘾研究队伍。该计划具有强大的机构 MGH领导层的支持。Evins博士和Rigotti的共同领导确保K12学者能够获得 多部门的多学科培训计划。指导计划包括培训学者1） 获得设计和实施成瘾医学临床研究所需的研究技能; 2）准备 科学论文和演讲; 3）撰写成功的资助申请; 4）负责任地进行研究， 5）在面向患者的成瘾研究中开展独立的职业生涯。他们将完成这一任务， 量身定制的课程工作，个人和小组会议，协作指导，以及与 通过MGH临床研究部和哈佛大学提供丰富的指导资源 催化剂（CTSC）计划。

Project Summary Training the next generation of clinician-investigators to conduct transformational, independent, patient- oriented addiction research that will improve the lives of those with addictive disorders is of the highest public health importance and is the primary goal of this MGH K12 Mentored Clinical Scientist Development Award in Drug Abuse and Addiction renewal application. This renewal will support and strengthen a multidisciplinary 2-3 year program of intensive training, mentored research, and dedicated career development mentorship for diverse, talented, post-doctoral clinician-scientists committed to independent research careers in patient- oriented addiction research provided in the rich training environment of addiction research laboratories based at the Massachusetts General Hospital (MGH), with advanced didactic training opportunities at MGH, McLean Hospital, and Harvard Medical School (HMS). These resources will continue to be individually tailored to each scholar’s interests in order to provide the focused, concentrated training and mentorship experience to optimally advance each Scholar’s productive, independent, impactful addiction-focused work, preparing them for leadership roles in clinical and academic medicine, government and industry. Career development support in the renewal will be bolstered by collaboration with a new national consortium of NIDA K12 scholars and mentors. Eden Evins, MD, MPH, and Nancy Rigotti, MD, will partner again as joint-PIs to lead the career development program renewal, supervising scholars’ research and career development, academic productivity, and progress to independence in patient-oriented addiction research. They are committed to attracting a diverse group of superb clinically-trained scholars, guided by an expanded Executive Committee and a 3- member Advisory Board of experienced leaders of successful postgraduate medical training programs to identify, recruit, retain and foster the career development of underrepresented in medicine (UiM) Scholar candidates. The mPIs are HMS Professors in the Departments of Psychiatry (Dr. Evins) and Medicine (Dr. Rigotti). They and their departments have a long history of productive collaboration and a shared vision for expanding a diverse, independent clinical addiction research workforce. The program has strong institutional support from MGH leadership. Dr. Evins’ and Rigotti’s co-leadership ensures that K12 scholars have access to a multi-departmental program of multi-disciplinary training. The mentoring plan includes training scholars to 1) acquire the research skills needed to design and implement clinical studies in addiction medicine; 2) prepare scientific papers and presentations; 3) write successful grant applications; 4) conduct research responsibly, and 5) launch independent careers in patient-oriented addiction research. They will accomplish this with tailored course work, individual and group meetings, collaborative mentoring, and role modeling integrated with the rich mentoring resources available through the MGH Division of Clinical Research and the Harvard Catalyst (CTSC) Program.